###begin article-title 0
Angiotensin II Type 1 Receptor Signaling Contributes to Synaptophysin Degradation and Neuronal Dysfunction in the Diabetic Retina
###end article-title 0
###begin p 1
###xml 37 63 37 63 <email xmlns:xlink="http://www.w3.org/1999/xlink">ishidasu@sc.itc.keio.ac.jp</email>
Corresponding author: Susumu Ishida, ishidasu@sc.itc.keio.ac.jp
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Pathogenic mechanisms underlying diabetes-induced retinal dysfunction are not fully understood. The aim of the present study was to show the relationship of the renin-angiotensin system (RAS) with the synaptic vesicle protein synaptophysin and neuronal activity in the diabetic retina.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-C57BL/6 mice with streptozotocin-induced diabetes were treated with the angiotensin II type 1 receptor (AT1R) blocker telimsartan or valsartan, and retinal function was analyzed by electroretinography. Retinal production of the RAS components and phosphorylation of ERK (extracellular-signal regulated kinase) were examined by immunoblotting. Retinal mRNA and protein levels of synaptophysin were measured by quantitative RT-PCR and immunoblot analyses, respectively. In vitro, synaptophysin levels were also evaluated using angiotensin II-stimulated PC12D neuronal cells cultured with or without the inhibition of ERK signaling or the ubiquitin-proteasome system (UPS).
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
RESULTS-Induction of diabetes led to a significant increase in retinal production of angiotensin II and AT1R together with ERK activation in the downstream of AT1R. AT1R blockade significantly reversed diabetes-induced electroretinography changes and reduction of synaptophysin protein, but not mRNA, levels in the diabetic retina. In agreement with the AT1R-mediated posttranscriptional downregulation of synaptophysin in vivo, in vitro application of angiotensin II to PC12D neuronal cells caused the UPS-mediated degradation of synaptophysin protein via AT1R, which proved to be induced by ERK activation.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-These data indicate the first molecular evidence of the RAS-induced synaptophysin degradation and neuronal dysfunction in the diabetic retina, suggesting the possibility of the AT1R blockade as a novel neuroprotective treatment for diabetic retinopathy.
###end p 6
###begin p 7
Published ahead of print at  on 16 May 2008.
###end p 7
###begin p 8
T.K. and Y.O. contributed equally to this work.
###end p 8
###begin p 9
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 9
###begin p 10
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
Diabetic retinopathy is a vision-threatening disease with neurodegenerative change due to chronically progressive microangiopathy. The earliest functional disruption clinically detectable is changes in oscillatory potentials (OPs) measured by electroretinography (ERG) (1,2). The cellular source of OPs is regarded as retinal neurons with synapse formation in the inner retina, including bipolar and amacrine cells (3). At present, there is no established neuroprotective treatment for diabetic retinopathy, since molecular mechanisms underlying diabetes-induced retinal neuronal damage remain unclear.
###end p 10
###begin p 11
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 342 343 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 588 589 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 590 591 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 717 718 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 719 721 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 867 868 863 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 890 892 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 920 922 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1168 1170 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 602 607 <span type="species:ncbi:9606">human</span>
We have recently demonstrated that angiotensin II type 1 receptor (AT1R) signaling contributes to diabetes-induced retinal inflammation such as leukocyte adhesion to the retinal vasculature (4). Angiotensin II functions as a proinflammatory factor to induce the activation of nuclear factor-kappaB pathway in microvascular endothelial cells (4). Angiotensin II is a final product of the renin-angiotensin system (RAS) produced from angiotensinogen through enzymatic cascade reactions, and the RAS components required for the generation of angiotensin II are reported to exist in the eye (5-7). Indeed, human surgical samples from eyes with diabetic retinopathy showed a significant increase in angiotensin II levels (8-10). Increasing evidence has suggested the contribution of the RAS to diabetes-induced retinal vascular complications including leukocyte adhesion (4), hyperpermeability (11), and impaired blood flow (12); however, little is known about the pathogenesis of angiotensin II-mediated neuronal dysfunction in the diabetic retina. Although AT1R blockade led to amelioration of hypertension-induced retinal dysfunction that was exacerbated with diabetes (13), no data have been reported that show the direct effect of AT1R signaling on diabetes-induced retinal dysfunction together with underlying molecular mechanisms.
###end p 11
###begin p 12
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
Recently, we revealed the coexpression of AT1R and the synaptic protein synaptophysin in the inner retinal neurons (14), consistent with several previous reports showing synaptic expression of AT1R in the brain (15-18). Synaptophysin, the major synaptic vesicle protein, is a marker of synapses reported to be reduced in the postmortem brains affected by several neurodegenerative diseases (19). Considering that OPs in ERG are originated from inner retinal neurons bearing AT1R, we hypothesize that angiotensin II directly induces synaptophysin dysregulation and visual functional damage represented by ERG changes. In the present article, we report the first evidence showing that AT1R signaling contributes to diabetes-induced retinal dysfunction and synaptophysin downregulation together with underlying molecular mechanisms.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin title 14
Induction of diabetes.
###end title 14
###begin p 15
###xml 8 12 <span type="species:ncbi:10090">mice</span>
C57BL/6 mice (Clea, Tokyo, Japan) at the age of 6 weeks were used in diabetes induction. All animal experiments were conducted in accordance with the ARVO (Association for Research in Vision and Ophthalmology) Statement for the Use of Animals in Ophthalmic and Vision Research. Animals received intraperitoneal injections of streptozotocin (Sigma, St. Louis, MO) at the dose of 60 mg/kg body weight for 3 days. Blood glucose concentrations were measured from the tail vein using Medisafe mini GR-102 (Terumo, Tokyo, Japan). Development of diabetes was defined by blood glucose >250 mg/dl 7 days after the first injection of streptozotocin.
###end p 15
###begin title 16
AT1R blockade in vivo.
###end title 16
###begin p 17
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were intraperitoneally injected with the AT1R blocker (ARB) telmisartan or valsartan (U.S. Pharmacopeia, Rockville, MD) at the dose of 5 or 10 mg/kg body weight, respectively, or vehicle (0.25% DMSO in PBS). The ARB treatment started 22 days after the first injection of streptozotocin for 6 consecutive days and continued until the end of the study (4-week diabetes at evaluation). The doses used in each ARB group were determined according to our previous study on diabetes-induced retinal inflammation (4). Telmisartan was a kind gift of Boehringer Ingelheim (Ingelheim, Germany).
###end p 17
###begin title 18
ERG analyses.
###end title 18
###begin p 19
###xml 1113 1114 1107 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 76 80 <span type="species:ncbi:10090">Mice</span>
###xml 564 568 <span type="species:ncbi:162683">Mayo</span>
Animals were dark-adapted for 12 h and prepared under dim red illumination. Mice were anesthetized with pentobarbital sodium at the dose of 70 mg/kg body weight and placed on a heating pad that maintained their body temperature at 35-36degreesC throughout the experiments. The pupils were dilated with a mixed solution of 0.5% tropicamide and 0.5% phenylephrine (Mydrin-P; Santen, Osaka, Japan). The ground electrode was a subcutaneous needle in the tail, and the reference electrode was placed subcutaneously between the eyes. The active contact lens electrodes (Mayo, Inazawa, Japan) were placed on the cornea. Recordings were performed with PowerLab system 2/25 (AD Instruments, New South Wales, Australia). Responses were differentially amplified at the gain of 1,000 times using an AC (alternate current)-coupled bioamplifier ML132 (AD Instruments) and filtered through a bandpass filter ranging from 0.3 to 500 Hz to yield a- and b-waves. OPs were simultaneously recorded using a high-pass filter set to 100 Hz, so that an overall bandpass ranging from 100 to 500 Hz was achieved. Light pulses of 800 cd-s/m2 were delivered via Ganzfeld System SG-2002 (LKC Technologies; Gaithersburg, MD). The amplitude and implicit time of the a- and b-waves and OPs were measured and compared among age-matched nondiabetic controls and 4-week diabetic animals treated with vehicle, telmisartan, or valsartan.
###end p 19
###begin title 20
In vitro assays.
###end title 20
###begin p 21
###xml 148 154 <span type="species:ncbi:9913">bovine</span>
###xml 169 174 <span type="species:ncbi:9796">horse</span>
The neuronal cell line PC12D cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and 10% horse serum (Medical & Biological Laboratories, Nagoya, Japan). Cells were incubated with 50 mug/mul of nerve growth factor (Millipore, Billerica, MA) for differentiation to neurons for 2 days. The neuronal cells were applied with the ARB telmisartan (10 mumol/l) or valsartan (25 mumol/l), the proteasome inhibitor MG132 or lactacystin (20 mumol/l for both; Calbiochem, San Diego, CA), the lysosome inhibitor E64 (50 mumol/l; Sigma), the extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 (10 mumol/l; Cell Signaling Technology, Beverly, MA) or PD98059 (10 mumol/l; Calbiochem), the phosphatidylinositol 3-kinase inhibitor LY294002 (20 mumol/l; Calbiochem) or wortmannin (100 nmol/l; Sigma), the Janus kinase inhibitor AG490 (1, 10, or 100 mumol/l; Calbiochem), or vehicle. After 5 min, the pretreated cells were subsequently stimulated with 100 nmol/l angiotensin II for 30 min. Immediately after the exposure to angiotensin II, the neuronal cells were subjected to quantitative RT-PCR and immunoprecipitation for synaptophysin and to immunoblot analyses for synaptophysin and phosphorylated forms of ERK1/2 (p44/p42), Akt (protein kinase B), and signal transducer and activator of transcription (STAT)-3.
###end p 21
###begin title 22
AT1R and ERK1/2 knockdown by RNA interference.
###end title 22
###begin p 23
###xml 219 222 <span type="species:ncbi:10116">Rat</span>
###xml 238 241 <span type="species:ncbi:10116">Rat</span>
###xml 260 263 <span type="species:ncbi:10116">Rat</span>
Transfections were performed using Lipofectamine 2000 (Invitrogen) and the SureSilencing short hairpin RNA (shRNA) kit (SuperArray Bioscience, Frederick, MD) according to the manufacturers' instructions. Briefly, 4 mug Rat Agtr1a (AT1R), Rat Mapk3 (ERK1), and Rat Mapk1 (ERK2) or control shRNA was incubated with 10 mul of the transfection reagent in 500 mul serum-free medium for 20 min to facilitate complex formation. The resulting mixture was added to PC12D cells cultured in a six-well plate with 2 ml medium for 48 h before differentiation.
###end p 23
###begin title 24
Quantitative RT-PCR analyses for synaptophysin.
###end title 24
###begin p 25
Animals were killed with an overdose of anesthesia. The eyes were immediately enucleated and the retina was carefully isolated. Total RNA was extracted from the retinas or PC12D cells using an extraction reagent (TRIzol; Invitrogen), and cDNA was synthesized with SuperScript III reverse transcriptase (Invitrogen). Real-time PCR was performed using MX3000 (Stratagene, La Jolla, CA) with PCR primers for synaptophysin designed by TaqMan Gene Expression Assays (Applied Biosystems, Foster, CA). The mRNA levels were normalized to beta-actin as an internal control.
###end p 25
###begin title 26
Immunoblot analyses for angiotensin II, AT1R, synaptophysin, and phosphorylated forms of ERK, Akt, and STAT3.
###end title 26
###begin p 27
###xml 412 418 <span type="species:ncbi:9986">rabbit</span>
###xml 661 666 <span type="species:ncbi:10090">mouse</span>
###xml 800 811 <span type="species:ncbi:3704">horseradish</span>
###xml 834 838 <span type="species:ncbi:9925">goat</span>
###xml 856 862 <span type="species:ncbi:9986">rabbit</span>
###xml 866 871 <span type="species:ncbi:10090">mouse</span>
###xml 956 967 <span type="species:ncbi:3704">horseradish</span>
The isolated retinas or PC12D cells were placed into lysis buffer (10 mmol/l Tris-HCl [pH 7.6], 100 mmol/l NaCl, 1 mmol/l EDTA, 1% Triton X-100, protease inhibitors). Each sample was separated with SDS-PAGE and electroblotted to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA). After nonspecific binding was blocked with 4% skim milk, the membranes were incubated at 4degreesC overnight with a rabbit polyclonal antibody against angiotensin II, AT1R (1:200, 1:100, respectively; Santa Cruz Biotechnology, Santa Cruz, CA), or phosphorylated forms of ERK, Akt, or STAT3 (1:1,000, 1:500, or 1:1,000, respectively; Cell Signaling Technology) or a mouse monoclonal antibody against synaptophysin (1:500; Sigma) or alpha-tubulin (1:2,000; Sigma). The membranes were then incubated with a horseradish peroxidase-conjugated goat antibody against rabbit or mouse immunoglobulins or with a biotinylated secondary antibody followed by avidin-biotin horseradish peroxidase complexes (Vectastain Elite ABC Kit; Vector, Burlingame, CA). The signals were visualized with chemiluminescence (ECL Blotting Analysis System; Amersham, Arlington Heights, IL), measured by ImageJ software (National Institutes of Health, Bethesda, MD) and normalized to alpha-tubulin.
###end p 27
###begin title 28
Ubiquitination assays.
###end title 28
###begin p 29
###xml 552 558 <span type="species:ncbi:9986">rabbit</span>
###xml 960 963 <span type="species:ncbi:10116">rat</span>
###xml 1111 1116 <span type="species:ncbi:10090">mouse</span>
PC12D cells were transfected with a hemagglutinin-ubiquitin plasmid (provided by Keiji Tanaka, the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) as described above at the time of differentiation. Forty-five hours after transfection, the cells were incubated for 3 h with 20 mumol/l MG132. The transfected cells were then pretreated with telmisartan, valsartan, or vehicle and followed by stimulation with angiotensin II as described above. The stimulated cells were placed into the lysis buffer, and the cell lysate was applied with a rabbit polyclonal antibody against synaptophysin (1:25; Sigma). After rocking at 4degreesC for 1 h, the lysate treated with anti-synaptophysin antibodies were then added with protein G-sepharose beads (Sigma) and incubated overnight at 4degreesC. After washes of nonspecific binding to beads, the bound protein was solubilized in sample buffer, loaded on an SDS-PAGE, and processed for immunoblotting with a rat monoclonal antibody against hemagglutinin (1:500; Roche Applied Science, Mannheim, Germany) to detect multi-ubiquitinated synaptophysin and with a mouse monoclonal antibody against synaptophysin (1:500; Sigma) to confirm the equal amount of synaptophysin protein applied in each lane.
###end p 29
###begin title 30
Statistical analysis.
###end title 30
###begin p 31
###xml 200 201 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
All results were expressed as means +/- SD. The values were processed for statistical analyses (one-way ANOVA with Tukey's post hoc test), and differences were considered statistically significant at P < 0.05.
###end p 31
###begin title 32
RESULTS
###end title 32
###begin title 33
Diabetes-induced retinal production of angiotensin II and AT1R led to ERK activation.
###end title 33
###begin p 34
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 202 209 202 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 344 351 344 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 512 518 512 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 596 597 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 661 668 661 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 669 670 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 772 773 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 901 902 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 907 908 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 895 908 895 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic> and <italic>E</italic></xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 889 893 <span type="species:ncbi:10090">mice</span>
###xml 1006 1010 <span type="species:ncbi:10090">mice</span>
Mice with streptozotocin-induced diabetes showed a significant (P < 0.05) decrease in body weight and a significant (P < 0.01) increase in blood glucose, compared with age-matched nondiabetic controls (Table 1). Treatment with telmisartan or valsartan of 4-week diabetic mice did not significantly (P > 0.05) change these metabolic parameters (Table 1). The retinas from 4-week diabetic mice were subjected to immunoblot analyses to detect the production of the RAS components and its downstream ERK activation (Fig. 1). Retinal levels of angiotensin II and its receptor AT1R were significantly (P < 0.01) higher in 4-week diabetic than in nondiabetic animals (Fig. 1A-C). Consistently, ERK phosphorylation, enhanced in 4-week diabetic mice (P < 0.01), was significantly (P < 0.01) attenuated by AT1R blockade with telmisartan or valsartan to the level equivalent with that in nondiabetic mice (Fig. 1D and E). In contrast, AT1R blockade did not attenuate the baseline level of retinal pERK in nondiabetic mice (data not shown).
###end p 34
###begin title 35
Diabetes-induced visual dysfunction was suppressed by AT1R blockade.
###end title 35
###begin p 36
###xml 70 76 70 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 125 131 125 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 590 591 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 640 641 636 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 646 647 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 634 647 630 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 749 750 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 822 823 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 828 829 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 816 829 812 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>C</italic></xref>
###xml 246 252 <span type="species:ncbi:10090">murine</span>
###xml 257 262 <span type="species:ncbi:9606">human</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
To determine the effect of the RAS activation in the diabetic retina (Fig. 1) on visual function, we performed ERG analyses (Fig. 2). OP changes including the reduced amplitude and prolonged implicit time are known to occur in the early stage of murine and human diabetic retinopathy (1,2,20,21). There was no remarkable difference in a- or b-wave among nondiabetes and 4-week diabetes treated with vehicle, telimsartan, and valsartan (data not shown). Importantly, AT1R blockade with telmisartan or valsartan significantly reversed the reduction of OP3 and total OPs (SigmaOPs) amplitude (P < 0.05 for both) in 4-week diabetic mice (Fig. 2A and B). Similarly, the implicit time of OP2 and OP3, prolonged in 4-week diabetic mice, was significantly (P < 0.05 for both) recovered by AT1R blockade to the normal level (Fig. 2A and C). In contrast, AT1R blockade did not alter normal ERG waves in nondiabetic mice (data not shown).
###end p 36
###begin title 37
Posttranscriptional reduction of synaptophysin in the diabetic retina was reversed by AT1R blockade.
###end title 37
###begin p 38
###xml 98 104 98 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 181 187 181 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 505 506 505 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 602 603 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 596 609 596 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic> and <italic>B</italic></xref>
###xml 805 806 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 799 806 799 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
To investigate the molecular mechanisms underlying the AT1R-mediated impairment of ERG responses (Fig. 2), we analyzed the regulation of the synaptic vesicle protein synaptophysin (Fig. 3), which is abundantly expressed in the inner retinal neurons (14), the cellular source of OPs (1,3,22,23). Synaptophysin is indispensable for several presynaptic functions, including the release of neurotransmitters (24). The retinal levels of synaptophysin protein, reduced by inducing diabetes, were significantly (P < 0.01) reversed in 4-week diabetic mice by AT1R blockade with telmisartan or valsartan (Fig. 3A and B). In contrast, mRNA levels of synaptophysin were unaltered in 4-week diabetic mice treated with vehicle, telimsartan, or valsartan, compared with those in age-matched nondiabetic controls (Fig. 3C). The discrepancy between the protein and mRNA levels indicated that the AT1R-mediated decline of synaptophysin in the diabetic retina was posttranscriptionally regulated. In contrast, AT1R blockade did not affect the physiologic level of synatophysin mRNA or protein in the nondiabetic retina (data not shown).
###end p 38
###begin title 39
AT1R-mediated posttranscriptional reduction of synaptophysin was regulated by the ubiquitin-proteasome system in neuronal cells.
###end title 39
###begin p 40
###xml 136 142 136 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 239 245 239 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 284 290 284 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 396 397 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 402 403 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 390 403 390 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic> and <italic>B</italic></xref>
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 420 427 420 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 604 605 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 598 605 598 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 607 608 607 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 616 617 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 869 870 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 863 870 863 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>G</italic></xref>
###xml 871 872 871 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 954 955 954 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 948 957 948 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic>&#8211;<italic>F</italic></xref>
###xml 1156 1157 1156 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1150 1157 1150 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>G</italic></xref>
###xml 1280 1281 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1364 1365 1364 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1370 1371 1370 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1358 1371 1358 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>H</italic> and <italic>I</italic></xref>
To elucidate the molecular mechanisms involving the AT1R-mediated posttranscriptional decrease in synaptophysin in the diabetic retina (Fig. 3), we used the in vitro culture system with PC12D neuronal cells stimulated with angiotensin II (Fig. 4). In agreement with the in vivo data (Fig. 3), in vitro application with angiotensin II significantly (P < 0.01) reduced synaptophysin protein (Fig. 4A and B), but not mRNA (Fig. 4C), levels in a posttranscriptional manner, which were significantly (P < 0.05 for all) reversed by AT1R blockade with telmisartan, valsartan, or shRNA for AT1R knockdown (Fig. 4A, B, and D-F). Because synaptic vesicle proteins including synaptophysin have recently proven to be physiologically degraded by the UPS for the maintenance of synaptic plasticity (25-27), we examined the involvement of the ubiquitin-proteasome system (UPS) (Fig. 4G-I) with AT1R-mediated posttranscriptional decrease in synaptophysin protein (Fig. 4A-F). Multi-ubiquitinated synaptophysin as a high-molecular weight smear, enhanced by stimulation with angiotensin II, was substantially attenuated by AT1R blockade with telmisartan or valsartan (Fig. 4G). Application with the proteasome inhibitor MG132 or lactacystin, but not the lysosome inhibitor E64, led to significant (P < 0.05) suppression of angiotensin II-induced degradation of synaptophysin (Fig. 4H and I). In contrast, the baseline levels of synaptophysin in PC12D cells not stimulated with angiotensin II were unaffected with these inhibitors (data not shown).
###end p 40
###begin title 41
AT1R-mediated ERK activation was required for synaptophysin degradation in neuronal cells.
###end title 41
###begin p 42
###xml 86 92 86 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 142 148 142 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 221 227 221 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 299 305 299 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 489 502 489 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic> and <italic>B</italic></xref>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 697 698 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 691 698 691 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 699 700 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1002 1003 1002 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 996 1003 996 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1004 1005 1004 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
Because ERK was activated in the downstream of AT1R signaling in the diabetic retina (Fig. 1), we examined the involvement of ERK activation (Fig. 5) with AT1R-mediated degradation of synaptophysin in the neuronal cells (Fig. 4). Consistent with AT1R-mediated ERK activation in the diabetic retina (Fig. 1), angiotensin II administration induced the phosphorylation of ERK in the neuronal cells, which was significantly (P < 0.05) inhibited by AT1R blockade with telmisartan or valsartan (Fig. 5A and B). Inhibition of ERK activation with U0126, PD98059, or shRNA for ERK1/2 knockdown led to significant (P < 0.05 for all) suppression of angiotensin II-induced degradation of synaptophysin (Fig. 5C-H). In addition to ERK signaling, phosphatidylinositol 3-kinase/Akt and Janus kinase/STAT pathways are known to be in the downstream of AT1R. In the neuronal cells, angiotensin II treatment also increased the phosphorylated forms of Akt and STAT3 (data not shown). In contrast to ERK involvement (Fig. 5C-H), however, the phosphatidylinositol 3-kinase inhibitor wortmannin or LY294002 or the Janus kinase inhibitor AG490 did not reverse angiotensin II-induced degradation of synaptophysin in vitro (data not shown).
###end p 42
###begin title 43
DISCUSSION
###end title 43
###begin p 44
###xml 322 328 322 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 443 449 443 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 706 712 706 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 858 864 858 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 953 959 953 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 1025 1031 1025 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
The present study reveals, for the first time to our knowledge, several important findings concerning the relationship of the RAS with diabetes-related neuronal damage in vivo and in vitro. In the diabetic retina, the RAS components angiotensin II and AT1R were upregulated together with AT1R's downstream ERK activation (Fig. 1). AT1R blockade with telmisartan or valsartan significantly reversed diabetes-induced OP changes measured by ERG (Fig. 2), known functional abnormalities in human diabetic retinopathy. Moreover, AT1R signaling caused a posttranscriptional decrease in the synaptic vesicle protein synaptophysin in the diabetic retina, which was rescued by the ARB application to diabetic mice (Fig. 3). The protein, but not mRNA, reduction of synaptophysin in neuronal cells was shown to depend on the UPS, which was enhanced via AT1R signaling (Fig. 4). Angiotensin II-induced neuronal ERK activation, also observed in the diabetic retina (Fig. 1), resulted in the degradation of synaptophysin protein in vitro (Fig. 5). The use of two different ARBs throughout the experiments confirmed that the suppression of diabetes-induced retinal dysfunction and synaptophysin degradation is a class effect for ARBs. Additionally, our in vitro results were further confirmed via gene-specific shRNA knockdown technique for AT1R and ERK.
###end p 44
###begin p 45
###xml 146 152 146 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 468 473 <span type="species:ncbi:9606">human</span>
In the diabetic retina, the production of angiotensin II and AT1R was upregulated, leading to ERK activation in the downstream of AT1R signaling (Fig. 1). Since ERK is known to be one of AT1R's signaling pathways, the present data are compatible with clinical (5,7,28,29) and experimental (4) studies showing increased angiotensin II generation in the diabetic eye. The cellular source of angiotensin II was shown to be retinal glial cells by immunohistochemistry for human postmortem eyes (30). In the liver and kidney as well (31-33), diabetes-induced activation of the RAS causes elevated concentration of tissue angiotensin II. The tissue RAS activation in diabetes is explained in part by the findings that in vitro stimulation with high glucose enhanced the transcriptional activity of angiotensinogen gene encoding a precursor protein for angiotensin I and II (34,35).
###end p 45
###begin p 46
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 364 370 364 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Our ERG analyses demonstrated the reduced amplitude and prolonged implicit time of OPs in diabetic mice, in accordance with clinical and experimental data on attenuated OP changes in early diabetes (1,2,29). Importantly, AT1R blockade significantly improved these functional parameters in the diabetic retina to the normal levels observed in nondiabetic controls (Fig. 2). Reasonably, the present ERG findings, in concert with our recent data on AT1R expression in the inner retinal neurons (14), the cellular origins of OPs, suggest that the functional recovery of the diabetic inner retina was attributable in part to the direct effect of AT1R blockade on the inner retinal neurons.
###end p 46
###begin p 47
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 326 332 326 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 524 530 524 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1191 1193 1191 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1416 1418 1416 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1589 1595 1589 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 1787 1793 1787 1793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 1913 1919 1913 1919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 1090 1094 <span type="species:ncbi:10090">Mice</span>
Several previous studies on neuronal damage in the diabetic retina showed the cellular changes including the apoptosis of ganglion and amacrine cells and the activation of glial cells (36-38). In contrast, the present study revealed, with the molecular changes in the diabetic retina, a significant decrease in synaptophysin (Fig. 3), the synaptic vesicle protein capable of maintaining the function of retinal neurons. Furthermore, AT1R signaling was shown to play a crucial role in the reduction of synaptophysin protein (Fig. 3). Pharmacologic studies using tetrodotoxin and glycine suggested the cellular origins of OPs as neurons with synapse formation in the inner retina including bipolar and amacrine cells (3,22,23), both of which develop a retinal neuronal network contributing to visual function. Synatophysin, a well-known marker for the presynapse, was shown to decrease with the progression of Parkinson's disease and Alzheimer's disease (19). In the retina as well, pathogenic conditions such as retinal detachment and inflammation caused reduction of synaptophysin (14,39). Mice deficient in synaptophysin exhibited a significant decrease in the number of synaptic vesicles (24). The neuron maintains its viability and activity by interacting with other neurons via synapses; however, synaptophysin knockouts were for the most part functionally compensated possibly because of biological redundancy (24). Although it is reasonable to think about the possibility of cooperative involvement of several other synaptic proteins, the diabetes-induced reduction of synaptopysin (Fig. 3) was attributable, at least in part, to the functional disturbance of neuronal activity in the diabetic retina. The currently observed suppression of synaptophysin decrease by AT1R blockade (Fig. 3) is likely to rescue the activity of the AT1R-bearing inner retinal neurons, leading to the improvement of OP changes (Fig. 2).
###end p 47
###begin p 48
###xml 27 34 27 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Figs. 4</xref>
###xml 39 40 39 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">5</xref>
###xml 188 194 188 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 336 343 336 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 381 387 381 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 534 541 534 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>G</italic></xref>
###xml 542 543 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 928 934 928 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1193 1195 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1231 1233 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1243 1253 1243 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 1409 1411 1409 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 1457 1467 1457 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 1651 1653 1651 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1719 1725 1719 1725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 1857 1859 1857 1859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 1860 1862 1860 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1941 1947 1941 1947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 2011 2017 2011 2017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 2078 2084 2078 2084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 1243 1253 <span type="species:ncbi:7227">Drosophila</span>
###xml 1457 1467 <span type="species:ncbi:7227">Drosophila</span>
The present in vitro data (Figs. 4 and 5) further elucidated the detailed molecular mechanisms underlying the AT1R-mediated posttranscriptional decrease in synaptophysin observed in vivo (Fig. 3). Angiotensin II directly exerted its bioactivity to the neuronal cells via AT1R, leading to a posttranscriptional decrease in synatophysin (Fig. 4A-F), which mimicked the in vivo data (Fig. 3). Interestingly, angiotensin II/AT1R signaling proved to cause the activation of the UPS, leading to synaptophysin degradation in neuronal cells (Fig. 4G-I). Although the UPS was recently shown to play a role in the degradation of several synaptic proteins (25-27), the present data are the first to reveal the RAS-mediated UPS activation for synaptic protein degradation in neurons. Out of several signaling molecules in the downstream of AT1R, the phosphorylation of ERK, but not Akt or STAT3, was required for synaptophysin degradation (Fig. 5), suggesting that the UPS-dependent synaptophysin degradation is mediated by ERK activation. This is supported by several recent studies showing that the activation of the ERK pathway promoted the UPS-mediated degradation of the cell cycle protein Cdc25 (40,41) and the cell survival factor Bim (42). In the Drosophila eye, ERK signaling was shown to be required for the physiologic activity of Sina (seven in absentia), a key molecule for normal photoreceptor development (43). Interestingly, the mammalian homologues of Drosophila Sina, Siahs (seven in absentia homologues), proved to be synaptophysin-binding proteins functioning as E3 ubiquitin ligases to regulate the UPS-mediated degradation of synaptophysin (26). Reasonably, baseline ERK phosphorylation in the normal retina (Fig. 1) is likely to play a physiologic role in the UPS-mediated degradation of synaptophysin for the maintenance of synaptic plasticity (25-27). In the diabetic retina, however, excessive ERK activation mediated by AT1R (Fig. 1) is thought to induce the pathologic decline of synaptophysin (Fig. 3), contributing to neuronal dysfunction demonstrated by ERG (Fig. 2).
###end p 48
###begin p 49
###xml 155 162 155 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Figs. 2</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">3</xref>
In the current study, diabetes-induced retinal dysfunction and synaptophysin downregulation were successfully reversed by AT1R signaling blockade in vivo (Figs. 2 and 3). Although future studies are required to determine whether angiotensin II/AT1R signaling leads to diabetes-induced neuronal damage systemically or locally in specific target organs, AT1R blockade has proven to be neuroprotective at least in the diabetic eye. Collectively, our present data show the possibility of AT1R blockade as a novel therapeutic strategy for neuronal dysfunction in vision-threatening diabetic retinopathy.
###end p 49
###begin p 50
###xml 54 58 <span type="species:ncbi:162683">Mayo</span>
The authors thank Masao Yoshikawa, Eiichiro Nagasaka (Mayo Company, Inazawa, Japan), and Hirobumi Tada (Yokohama City University, Yokohama, Japan) for expert advice and Haruna Koizumi and Taiga Shioda (Keio University, Tokyo, Japan) for technical assistance. This study was supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant-in-Aid for Scientific Research [number 19791289] to T.K. and the 21st Century COE Program at Keio University).
###end p 50
###begin p 51
This work was presented in part at the 2007 annual meeting of ARVO (Association for Research in Vision and Ophthalmology) in Fort Lauderdale, FL.
###end p 51
###begin title 52
REFERENCES
###end title 52
###begin p 53
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 323 324 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 325 326 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 461 462 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 467 468 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 323 326 <span type="species:ncbi:10090">A-C</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
Diabetes-induced retinal production of angiotensin II and AT1R led to ERK activation. Immunoblot analyses showing the production of the RAS components (A-C) and ERK activation in the diabetic retina (D and E). Retinal levels of angiotensin II and AT1R were significantly higher in 4-week diabetic than in nondiabetic mice (A-C). ERK phosphorylation, elevated in 4-week diabetic mice, was significantly attenuated by AT1R blockade with telmisartan or valsartan (D and E). n = 4 for all. *P < 0.05.
###end p 53
###begin p 54
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 458 459 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 464 465 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 468 469 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 478 479 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 490 491 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
Diabetes-induced visual dysfunction was suppressed by AT1R blockade. A: Representative wave responses from an individual mouse in each group to one flash. A and B: ERG analyses showing that AT1R blockade with telmisartan or valsartan significantly reversed the reduction of OP3 and total OPs (SigmaOPs) amplitude in 4-week diabetic mice. Similarly, the implicit time of OP2-3, prolonged in 4-week diabetic mice, was significantly recovered by AT1R blockade (A and C). n = 7-9. *P < 0.05, **P < 0.01.
###end p 54
###begin p 55
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 282 283 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 470 471 470 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 484 485 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
Posttranscriptional reduction of synaptophysin in the diabetic retina was reversed by AT1R blockade. The retinal levels of synaptophysin protein, reduced by inducing diabetes, were significantly reversed in 4-week diabetic mice by AT1R blockade with telmisartan or valsartan (A and B). In contrast, mRNA levels of synaptophysin were unaltered in 4-week diabetic mice treated with vehicle, telmisartan, or valsartan compared with age-matched nondiabetic control animals (C). n = 4-8. *P < 0.05, **P < 0.01.
###end p 55
###begin p 56
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 388 389 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 439 440 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 796 797 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 802 803 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 806 807 806 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 388 391 <span type="species:ncbi:10090">A-C</span>
AT1R-mediated posttranscriptional reduction of synaptophysin was regulated by the UPS in neuronal cells. In vitro application with angiotensin II significantly reduced synaptophysin protein (A and B), but not mRNA (C), levels in a posttranscriptional manner, which were significantly reversed by AT1R blockade with telmisartan or valsartan. The data with the pharmacologic AT1R blockade (A-C) were reproduced via shRNA for AT1R knockdown (D-F). Multi-ubiquitinated synaptophysin as a high-molecular weight smear, enhanced by stimulation with angiotensin II, was substantially attenuated by AT1R blockade (G). Application with the proteasome inhibitor MG132 or lactacystin, but not the lysosome inhibitor E64, led to significant suppression of angiotensin II-induced degradation of synaptophysin (H and I). n = 4-6. *P < 0.05, **P < 0.01.
###end p 56
###begin p 57
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 407 408 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 459 460 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 461 462 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 512 513 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 514 515 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 540 541 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
AT1R-mediated ERK activation was required for synaptophysin degradation in neuronal cells. Angiotensin II administration induced the phosphorylation of ERK in the neuronal cells, which was significantly inhibited by AT1R blockade with telmisartan or valsartan (A and B). Inhibition of ERK activation with U0126 or PD98059 led to significant suppression of angiotensin II-induced decline of synaptophysin (C-E). The data with the pharmacologic ERK inhibition (C-E) were reproduced via shRNA for ERK1/2 knockdown (F-H). n = 4-6. *P < 0.05, **P < 0.01.
###end p 57
###begin p 58
Systemic data
###end p 58
###begin p 59
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.05,
###end p 59
###begin p 60
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
P < 0.01 vs. nondiabetes.
###end p 60

